Summary
This clinical study examined G-CSF treatment outcomes in hospitalised infants with neutropenia. Whilst G-CSF accelerated hematologic recovery, it was associated with increased odds of secondary sepsis and mortality, leading the authors to conclude that routine G-CSF use is not recommended in this population.
Regional applicability
The findings are directly applicable to UK paediatric practice, as the safety and efficacy profile of G-CSF in neonatal populations is relevant to NHS guidance on managing neutropenia in hospitalised infants. The recommendation against routine use may inform clinical protocols in UK neonatal units.
Key measures
Time to hematologic recovery; incidence of secondary sepsis; mortality rates
Outcomes reported
The study evaluated the effectiveness of granulocyte colony-stimulating factor (G-CSF) treatment in hospitalised infants with neutropenia, measuring time to hematologic recovery, secondary sepsis incidence, and mortality.
Funding & declared interests
Funding: Best Pharmaceuticals for Children Act
Extracted verbatim from the paper’s funding, acknowledgements and conflict-of-interest sections — shown as neutral provenance, not a judgement on the research.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.